Trial · NCT07903597
Perception of the Benefits and Effectiveness of Inhalation Therapy in Patients With Obstructive Dyspnea
NCT07903597, Completed, Istituti Clinici Scientifici Maugeri SpA
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perception of the Benefits and Effectiveness of Inhalation Therapy in Patients With Obstructive Dyspnea. Trials, record NCT07903597. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903597
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perception of the Benefits and Effectiveness of Inhalation Therapy in Patients With Obstructive Dyspnea
- NCT number
- NCT07903597
- Status
- Completed
- Enrollment
- 101 participants, actual
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Conditions
- COPD, Asthma
- Interventions
- Survey
- First posted
- 2026-10-29
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AUDIT | Baseline | The structured interview must cover several areas of investigation, namely: 1. specifically, patients' perceptions and opinions regarding inhalation therapy (e.g., administration methods, frequency, and ease of use; perceived effectiveness; reasons for prescription; and perceived severity of the disease associated with this therapy); 2. the patient's awareness of and knowledge about the disease, 3. perceptions of therapy in general and patient preferences; and 4. motivation to adhere to prescriptions. |
| Secondary | QUESTIONNAIRE | Starting from month 1 | The final version of the questionnaire is organized into four sections. The first part of the questionnaire is designed to collect the patient's medical history: it includes questions about education level, employment, presence of a caregiver, type of diagnosis and its duration, the type of inhalation therapy used, number of administrations, presence of comorbidities, other medications taken, and whether the patient is autonomous in managing his/her pharmacological therapy. The second part of the questionnaire explores the patients' perception of their condition. The third part focuses on therapies in general, while the fourth and final section concentrates exclusively on inhalation therapy. The questionnaire does not yield an overall score, and therefore no minimum or maximum total score can be determined. Accordingly, each item will be considered and analyzed individually. |
| Secondary | BELIEFS | Starting from month 1 | In addition to the structured interview, participants completed questionnaires evaluating treatment perceptions and beliefs about medication. The Beliefs about Medicines Questionnaire (BMQ), a validated instrument designed to assess cognitive representations of medication, was included in the study protocol. Patients rated their agreement with each statement on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The BMQ comprises a Specific section, assessing beliefs about the necessity of prescribed medications and concerns related to their use, and a General section, evaluating beliefs about medicines as a class of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903597
GET https://conductscience.org/api/trials/v1/NCT07903597/registered